Techno Drugs Income Statement

Financials in millions BDT. Fiscal year is July - June.

Millions BDT. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Revenue	3,127	3,613	2,733	5,029
Revenue Growth (YoY)	14.39%	32.19%	-45.64%	-
Cost of Revenue	1,829	2,098	1,579	3,224
Gross Profit	1,298	1,515	1,154	1,804
Selling, General & Admin	720.14	848.23	628.04	905.09
Operating Expenses	720.14	848.23	628.04	905.09
Operating Income	577.51	666.8	526	899.4
Interest Expense	-327.53	-305.93	-263.87	-256.61
Interest & Investment Income	2.55	2.55	2.62	11.97
Currency Exchange Gain (Loss)	-0.19	-0.19	-0.01	-
Other Non Operating Income (Expenses)	-2.08	-3.64	-5.69	-3.74
Pretax Income	250.26	359.59	259.05	651.02
Income Tax Expense	27.56	78.99	63.55	171.24
Net Income	222.71	280.6	195.51	479.78
Net Income to Common	222.71	280.6	195.51	479.78
Net Income Growth	13.91%	43.53%	-59.25%	-
Shares Outstanding (Basic)	124	95	94	94
Shares Outstanding (Diluted)	124	95	94	94
Shares Change (YoY)	31.22%	1.34%	-	-
EPS (Basic)	1.80	2.94	2.08	5.10
EPS (Diluted)	1.80	2.94	2.08	5.10
EPS Growth	-13.19%	41.62%	-59.25%	-
Free Cash Flow	-612.73	83.64	-416.28	-1.52
Free Cash Flow Per Share	-4.96	0.88	-4.42	-0.02
Dividend Per Share	-	1.200	-	-
Gross Margin	41.50%	41.93%	42.22%	35.88%
Operating Margin	18.47%	18.45%	19.24%	17.89%
Profit Margin	7.12%	7.77%	7.15%	9.54%
Free Cash Flow Margin	-19.60%	2.31%	-15.23%	-0.03%
EBITDA	925.89	990.74	817.36	1,151
EBITDA Margin	29.61%	27.42%	29.90%	22.89%
D&A For EBITDA	348.38	323.94	291.35	251.54
EBIT	577.51	666.8	526	899.4
EBIT Margin	18.47%	18.45%	19.24%	17.89%
Effective Tax Rate	11.01%	21.97%	24.53%	26.30%
Advertising Expenses	-	0.76	0.26	0.59

Source: S&P Global Market Intelligence. Standard template. Financial Sources.